[ad_1]
Pfizer realized in mid-November that it would not be possible to guarantee the production of 100 million doses by the end of this year, as it had planned. A problem with one or more components of the vaccine caused the The pharmaceutical company can only guarantee half of the expected delivery., news or journal The Wall Street Journal.
In order to guarantee deliveries, Pfizer would have to increase its production capacity considerably, since the company had never before produced a large-scale vaccine based on mRNA technology. The lack of quality in some (or several) components caused the process to be delayed.
Typically, pharmaceutical companies only start large-scale production after regulators have approved vaccines or drugs. In this case, Production began even before the first preliminary results of the phase 3 clinical trial were known.. In addition, the production and distribution chain began to be configured from March.
Pfizer and BioNTech guarantee that they will be able to produce the 1.3 billion vaccines planned for 2021 and that the remaining 50 million will also be produced as soon as factories can.
The UK is already receiving the vaccines that it will start administering on Monday. The American newspaper reports that the British order amounts to 40 million doses to vaccinate 20 million people, of the 68 million who live in the United Kingdom. The British government hoped to receive 10 million doses before the end of the year, but was only able to receive four to five million.
[ad_2]
